About Us | MetXBio

Our History & Scientific Authority

MetxBio is founded upon a proven heritage of over 30 years in innovating, developing and validating antimicrobial platforms, with a primary focus on integration into complex medical devices and critical healthcare environments. We stand as a recognised global centre of excellence dedicated to delivering precise, high-performance solutions across various target application areas.

The Innovation: Multifunctional Molecular Complex (MMC)

Our core breakthrough is the proprietary Multifunctional Molecular Complex (MMC) technology. This advanced antibiofilm platform utilizes a sophisticated chemical design: a complex of specific chelating agents paired with multiple metal ions chosen for their known biological functionality, in conjunction with non-metal antimicrobials and surfactants if the partnering company requires this.

The MMC system achieves its efficacy through a powerful dual mechanism of action (MoA), ensuring comprehensive control over biofilm structures and their constituent microorganisms:

Biofilm Deconstruction: The integrated chelators effectively target and disrupt the Extracellular Polymeric Substance (EPS) matrix by binding essential divalent metal cations (e.g., Ca2+ or Mg2+). This action compromises the structural integrity of the biofilm, leading to rapid dissolution and microbial dispersal.
Microbial Eradication: Following disruption, the MMC facilitates the controlled release of potent metal ions (e.g., Ag+ or Zn2+), providing broad-spectrum antimicrobial activity. These ions effectively kill the freed microorganisms and inhibit the subsequent attachment and formation of new biofilms on the treated surface.

This rigorous, multifunctional approach offers a definitive solution for achieving clinical-grade antibiofilm and antimicrobial protection.

Meet the team

Meet the MetXBio Leadership Team

Our MetXBio Group senior management team is responsible for making sure that we continually enhance the quality and standards of the MetXBio and ensure we deliver above and beyond the expectations of all our customer needs.

Chief Executive Officer

Steven has over 28 years’ experience at senior management and Vice President levels in R&D, commercial and general management gained in FTSE 100, AIM listed and privately owned companies involved in medical device development, biomedical R&D, academic research and public health.

He has also invented and developed many medical devices that continue to be sold globally. Steven also holds the position of honorary Professor at The University of Liverpool. He has a PhD in biofilms and microbiology, an MSc in Health Sciences, an MSc in Medical Microbiology and a diploma in business administration. He has written over 430 scientific publications and conference abstracts and edited/authored eight textbooks and provided over 300 presentations worldwide. He sits on many international panels and industrial advisory boards linked to medical devices, woundcare, biofilms, antimicrobials, infection prevention and control.

Finance Director

Martin is a CIMA Qualified accountant with over 30 years experience at Financial Director level.

He has extensive experience in the pharmaceutical, biomedical and biotechnology industries having worked at Corning Inc, J Bibby Science Products, Advanced Medical Solutions Plc and Sants Pharmaceuticals. With a good understanding of a range of manufacturing industries, Martin uses his commercial insight to streamline business processes, improve financial control, and increase efficiency.

Non-Executive Director

Karen is a lawyer with over 30 years legal experience, is qualified to practice law in the U.K. and the U.S. (Florida), and is a Governance Professional.

In addition to her professional qualifications she holds an LL.B (hons) and a Juris Doctor (cum laude). She has worked in private practice in the U.K., the U.S. and Hong Kong and in-house in the U.S. for Tech Data Corporation and in the U.K. for Alfred McAlpine Plc and Advanced Medical Solutions Group Plc. She has served as a non-executive on the board of Parkhaven Trust, a residential care home charity and is a current non-executive trustee for the SBA, the Solicitors’ Charity.

Senior Scientist – Biomaterials, Tissue Engineering & Biologics

Dr Chen has over 20 years experience in the fields of cell biology, biocompatibility, inflammation, wound modelling, biomaterials, tissue engineering and product development.

Dr Rui Chen gained his PhD in Biomedical Engineering in 2001 and then developed a successful research career as a PDRA and senior scientist working with a number of research groups around the world developing his reputation as an expert in the field of biomaterials, cell biology and tissue engineering. He has published a number of high impact rated research papers and presented his pioneer research at local and international conferences.

Senior Scientist – Biosensors, Biomarkers & Diagnostics

Marcus has over 30 years’ experience of scientific research and development and in bringing sensing and measurement technologies to market, principally in the areas of surface analysis and biosensing.

He has worked both in academia and industry and has collaborated with international groups in universities and in support of commercial R&D. Marcus has a Ph.D. from the University of Bristol in Electrochemistry and has contributed to over 90 scientific publications and patents.

Our Mission Statement

At MetxBio, we leverage advanced biotechnology to provide comprehensive biofilm solutions. Our purpose is to empower global partners with the ability to prevent formation, control proliferation, manage risk, and exploit inherent biofilm properties, delivering new customer benefits and securing definitive competitive advantage.